Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025-FY EPS reported $1.21 revenue$1,500,000,000

Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).
Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).
Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.
2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.
2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.